1099-1069/asset/olalertbanner.jpg?v=1&s=5a2e5e22ad4ef4d48186ee37f977bc7094efd01d)
| ABT-199, 37, 108, 109, 147, 261 |
| ABVD, 8, 41, 82, 118, 171, 253, 325, 326, 328, 464 |
| activated B-cell-like (ABC), 25, 49, 50, 136, 158, 214 |
| AKT, 397 |
| ALK, 240, 241 |
| allogeneic stem cell transplant (alloSCT), 30, 33, 34, 56, 68, 180, 247, 330, 333, 349, 395, 468 |
| anaplastic large cell lymphoma (ALCL), 68, 73, 84, 100, 181, 239, 240, 241, 315, 329, 435, 916, 917 |
| angioimmunoblastic T-cell lymphoma (AITL), 40, 72, 84, 101, 112 |
| anthracycline, 216, 377, 445, 447 |
| antibody-dependent cytotoxicity (ADC), 275, 276 |
| apoptosis, 152, 265, 269, 275, 471 |
| Ara-C, 59, 352, 373, 386 |
| Array-comparative genomic hybridization, 21, 26, 72, 316 |
| aurora kinase, 279 |
| autologous stem cell transplantation (ASCT), 9, 29, 30, 31, 62, 68, 74, 102, 119, 120, 180, 200, 209, 247, 303, 331, 333, 345, 349, 351, 373, 386, 388, 389, 390, 392, 393, 394, 432, 437, 443 |
| B-cell lymphoma, 2, 17, 18, 22, 23, 27, 38, 39, 55, 79, 91, 96, 107, 116, 139, 142, 149, 155, 156, 158, 186, 280, 281, 286, 287, 290, 302, 304, 313, 338, 347, 368, 369, 376, 388, 398, 405, 447, 449, 469, 474, 477, 478, 479, 481, 904, 908, 912 |
| B-cell receptor (BCR), 22, 38, 39, 51, 94, 105, 153, 165, 264 |
| B-cells, 183 |
| BCL2, 161, 162, 261, 307, 308, 309, 311, 362, 422, 476 |
| BCL6, 162, 225, 362 |
| BEACOPP, 8, 118 |
| BEAM, 29, 388 |
| bendamustine, 13, 15, 56, 59, 60, 62, 90, 123, 178, 198, 249, 341, 390, 452 |
| bleomycin, 41 |
| bortezomib, 57, 109, 202, 438, 440, 911 |
| brentuximab vedotin, 87, 88, 89, 90, 91, 92, 120, 177, 178, 306, 329, 330, 333, 435, 436, 916, 917, 918 |
| bromodomains, 36, 270, 271, 272 |
| BTK, 472, 481, 906 |
| Burkitt lymphoma (BL), 21, 46, 51, 66, 67, 114, 116, 222, 289, 479 |
| carboplatin, 373 |
| CD19, 139, 140, 285, 312 |
| CD20, 105, 123, 201, 275 |
| CD22, 381 |
| CD3, 285 |
| CD30, 91, 92, 120, 177, 181, 329, 330, 916, 917 |
| CD37, 141, 274, 286, 287 |
| CD5, 312, 313 |
| chemokines, 281, 405, 452 |
| Chemotherapy, 31, 46, 67, 89, 103, 125, 179, 218, 228, 234, 236, 243, 245, 248, 251, 260, 273, 313, 351, 352, 371, 376, 414, 432, 433, 446, 448, 469 |
| chromosomal translocations, 26, 37, 146 |
| chronic lymphocytic leukemia (CLL), 13, 38, 42, 45, 53, 54, 55, 56, 95, 98, 105, 106, 141, 169, 170, 182, 183, 184, 185, 263, 284, 288, 313, 314, 456, 903, 906, 914, 915, 919, 922 |
| classical Hodgkin lymphoma (cHL), 10, 23, 28, 118, 176, 181, 295, 309, 316, 320, 328, 464, 465, 469, 475, 478, 922 |
| CNS prophylaxis, 220, 221, 368, 422 |
| cutaneous anaplastic large cell lymphoma (cALCL), 73 |
| cutaneous B-cell lymphoma (CBCL), 412, 413 |
| cutaneous T-cell lymphoma (CTCL), 40, 276, 277, 298, 434, 436 |
| cyclins, 26, 57 |
| cyclophosphamide, 450 |
| cytogenetics, 37, 55, 109, 239, 290 |
| cytokines, 167, 201, 281, 915 |
| DA-R-EPOCH, 393 |
| Deauville's criteria, 81, 258, 355, 464, 466 |
| deep sequencing, 19, 20, 112, 133, 155, 163, 165, 316, 399 |
| dendritic cells, 480, 912 |
| dexamethasone (DXM), 471 |
| DHAP, 283, 374, 911 |
| diffuse large B-cell lymphoma (DLBCL), 15, 19, 21, 28, 35, 36, 39, 46, 48, 49, 50, 78, 79, 80, 83, 86, 91, 92, 93, 97, 106, 115, 126, 127, 128, 129, 130, 131, 133, 136, 140, 144, 145, 146, 147, 152, 153, 155, 156, 157, 158, 159, 160, 161, 163, 164, 200, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 223, 224, 226, 228, 229, 252, 257, 258, 260, 262, 265, 267, 268, 269, 270, 271, 274, 282, 283, 284, 285, 295, 299, 300, 302, 303, 305, 306, 307, 311, 317, 318, 345, 356, 357, 358, 359, 361, 362, 363, 364, 366, 367, 371, 372, 373, 374, 375, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 397, 403, 418, 419, 455, 458, 460, 462, 466, 467, 476, 481, 482, 483, 905, 908, 911, 913 |
| DNA microarrays, 163, 164, 289 |
| doxorubicin, 87, 251, 445, 446, 448 |
| “double-hit” lymphomas, 110, 115, 146, 161, 162, 304 |
| EBER, 367 |
| elderly, 60, 89, 134, 185, 203, 216, 217, 231, 232, 300, 377, 380, 382, 384, 394, 403, 404, 441, 913 |
| epigenetics, 36, 144, 145, 170, 271, 272, 305 |
| Epstein-Barr virus (EBV), 95, 97, 299, 300, 301, 367, 396, 427, 438, 921 |
| ERK, 186, 471 |
| ESHAP, 385 |
| etiology principles, 50 |
| etoposide, 99 |
| extranodal lymphomas, 75, 102, 103, 210, 219, 228, 229, 234, 238, 244, 245, 315, 318, 378, 402, 403, 417, 418, 420, 421, 424, 427, 428, 429, 470, 920, 921 |
| extranodal marginal zone lymphoma of MALT type, 124, 230 |
| EZH2, 145 |
| F-18-fluorodeoxyglucose (FDG), 8, 254, 461, 465, 469, 470 |
| flow cytometry, 150, 151, 237, 296, 312, 437 |
| fludarabine, 340 |
| fluorescence in situ hybridization (FISH), 18, 239 |
| follicular lymphoma (FL), 11, 22, 24, 25, 29, 30, 52, 121, 122, 142, 145, 147, 148, 150, 151, 187, 188, 189, 190, 191, 192, 193, 195, 196, 197, 256, 267, 284, 293, 294, 316, 335, 336, 338, 339, 340, 341, 345, 346, 348, 349, 376, 457, 458, 480, 904, 907, 910, 912 |
| fostamatinib, 265 |
| GCB lymphoma subtype, 25, 157, 300 |
| gemcitabine, 246, 381, 387, 425 |
| gene expression profile (GEP), 25, 35, 93, 112, 114, 115, 127, 214, 266, 278, 291, 477 |
| gene rearrangement, 18, 19, 292 |
| germinal center (GC), 17 |
| germinal center B cell-like (GCB), 49, 158, 214, 221, 257 |
| Helicobacter pylori, 411 |
| hepatitis B, 96, 98, 366, 454, 455 |
| hepatitis C, 343, 366, 379, 409 |
| hepatosplenic T-cell lymphoma, 71 |
| high-dose steroids, 444 |
| high-dose therapy (HDT), 157, 247, 386, 450 |
| highly active anti-retroviral therapy (HAART), 325, 370 |
| histone deacetylase inhibitors, 16, 80, 104, 224, 279, 477 |
| Hodgkin lymphoma (HL), 8, 41, 43, 44, 46, 82, 87, 88, 89, 90, 94, 107, 119, 120, 126, 171, 172, 173, 174, 175, 177, 178, 179, 180, 253, 254, 255, 259, 266, 278, 297, 301, 302, 320, 321, 322, 323, 325, 326, 327, 329, 330, 331, 332, 333, 334, 387, 456, 459, 463, 482, 916 |
| human herpes virus (HHV), 201 |
| human immunodeficiency virus (HIV), 201, 218, 302, 310, 325, 369, 370 |
| human T-lymphotropic virus (HTLV), 113 |
| hyper-CVAD, 62 |
| ibritumomab tiuxetan, 340, 384 |
| ibrutinib, 55, 77, 78, 105, 106, 108, 136, 165, 207, 208, 261, 273, 344, 477, 906, 909 |
| ICE, 380, 415 |
| Idelalisib (CAL-101, GS-1101), 42, 45, 193, 194, 273, 280, 473 |
| immune system, 24, 127, 240, 480 |
| immunochemotherapy, 10, 130, 188, 191, 195, 197, 200, 220, 222, 356, 357, 480, 912, 914 |
| Immunoconjugates, 274 |
| immunodeficiency-associated lymphomas, 369, 918 |
| immunoglobulins (Ig), 155, 292 |
| immunohistochemistry (IHC), 24, 115, 148, 294, 297, 306, 308, 311, 439 |
| immunomodulators (IMIDs), 16, 137, 206, 342, 354, 439 |
| immunophenotype, 149, 150, 238, 305, 307, 426 |
| immunosuppression, 97, 295, 396, 918 |
| immunotoxins, 381 |
| indolent lymphoma, 123, 142, 186, 192, 237, 287, 342, 343, 401, 409, 904, 907, 920 |
| induction treatment, 70, 103, 231, 232, 372, 903 |
| interleukines, 915 |
| JAK/STAT, 36, 79, 107, 156, 237 |
| Ki-67, 58, 408, 909 |
| L-asparaginase, 75, 248, 425, 430 |
| lenalidomide, 5, 11, 12, 13, 14, 15, 16, 60, 78, 101, 137, 191, 205, 206, 209, 273, 354, 374, 385, 442, 905, 910 |
| lomustine, 331 |
| lymphoblastic lymphoma (LBL), 65, 69, 471 |
| lymphoplasmacytic lymphoma (LPL), 125 |
| macrophages, 137, 358 |
| magnetic resonance imaging (MRI), 85 |
| MALT1, 124 |
| mantle cell lymphoma (MCL), 2, 14, 26, 57, 58, 59, 60, 61, 62, 165, 166, 167, 168, 202, 203, 204, 205, 206, 207, 208, 209, 261, 272, 290, 312, 350, 351, 352, 353, 354, 355, 472, 909 |
| marginal zone lymphoma (MZL), 12, 198, 230, 337, 408, 410, 411, 910 |
| methotrexate (MTX), 75, 221, 226, 248, 372, 404 |
| microRNA, 22, 153, 271 |
| minimal residual disease (MRD), 59, 204, 437 |
| molecular genetics, 17, 18, 20, 51, 114, 144, 260, 288, 289, 292, 483, 908 |
| monoclonal antibodies (MoAb), 29, 40, 140, 141, 286 |
| monoclonal gammopathy of undetermined significance (MGUS), 5 |
| mouse models, 51, 113, 144, 260, 264 |
| mTor inhibitors, 250, 282, 472 |
| Mucosa-Associated Lymphoid Tissue (MALT), 401, 418, 920 |
| multiple myeloma (MM), 5, 10, 37, 80, 109, 168, 319, 438, 439, 440, 441, 442, 443, 458, 922 |
| MYC, 110, 114, 116, 157, 159, 161, 162, 262, 289, 303, 308, 311, 473 |
| mycosis fungoides (MF), 436 |
| MYD88, 77, 108, 125, 132, 159, 160, 270, 908 |
| NF-kB, 262, 268, 270, 475 |
| nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), 94, 324 |
| non-Hodgkin lymphoma (NHL), 10, 17, 20, 27, 45, 65, 69, 75, 102, 106, 121, 129, 142, 147, 148, 149, 154, 174, 193, 199, 242, 264, 266, 269, 275, 286, 298, 310, 319, 327, 331, 332, 347, 350, 359, 360, 365, 370, 387, 390, 391, 394, 395, 400, 402, 405, 419, 421, 427, 428, 431, 445, 451, 453, 456, 461, 470, 481, 904, 910, 921, 922 |
| obinutuzumab, 123, 906, 914, 915 |
| ofatumumab, 198, 199, 920 |
| P53, 116, 168, 288, 290 |
| PAX5, 269 |
| performance status, 359 |
| peripheral T-cell lymphomas (PTCL), 33, 70, 72, 74, 84, 100, 231, 232, 233, 235, 246, 247, 249, 399, 425, 426, 430, 433, 435, 437 |
| PI3K/AKT/mTOR, 35, 38, 42, 45, 57, 78, 79, 80, 107, 110, 193, 263, 266, 267, 268, 280, 281, 284, 397, 442, 473, 907 |
| positron emission tomography (PET), 81, 82, 83, 84, 118, 119, 173, 175, 204, 210, 215, 223, 252, 255, 256, 257, 258, 326, 355, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 901 |
| post-transplant lymphoproliferative disorders (PTLDs), 179, 396, 407, 423 |
| pralatrexate, 104 |
| primary CNS lymphoma (PCNSL), 9, 85, 133, 134, 135, 136, 137, 225, 227, 403, 404, 405, 406, 483 |
| primary mediastinal large B-cell lymphoma (PMLBCL), 28, 48, 49, 81, 156, 327, 414, 415, 416, 901 |
| prognostic indices, 24, 54, 70, 74, 81, 95, 99, 124, 126, 127, 130, 170, 179, 188, 210, 213, 233, 240, 314, 319, 346, 356, 357, 358, 363, 364, 367, 408, 426, 430, 465 |
| proteasome, 278, 442, 473 |
| PTEN, 267 |
| PTLD, 21, 918 |
| R-ACVBP, 215 |
| R-CHOP, 92, 128, 202, 215, 217, 218, 258, 282, 307, 357, 359, 360, 364, 366, 372, 382, 383, 413, 415, 448, 905 |
| R-FC, 185 |
| radioimmunotherapy (RIT), 128, 204, 287, 340, 341, 384 |
| reduced-intensity conditioning regimen (RIC), 349 |
| Reed-Sternberg cells, 475 |
| rituximab, 9, 11, 12, 15, 122, 126, 130, 183, 184, 187, 191, 195, 196, 197, 199, 213, 222, 223, 226, 252, 274, 283, 304, 345, 346, 347, 348, 351, 363, 383, 385, 393, 396, 398, 449, 905, 909 |
| romidepsin (RD), 16, 246, 279, 434, 902 |
| salvage treatment, 14, 119, 178, 180, 224, 246, 334, 374, 375, 387, 400, 410, 911 |
| Sezary syndrome, 40, 276, 436 |
| SNP, 292 |
| splenectomy, 409 |
| splenic marginal zone lymphoma (SMZL), 272, 409 |
| subcutaneous panniculitis-like T-cell lymphoma (SPTL), 236 |
| SYK, 39, 42, 265 |
| T-cell lymphoma (TCL), 23, 31, 32, 71, 99, 104, 113, 235, 236, 238, 242, 243, 244, 248, 250, 278, 279, 369, 429, 431, 432, 458, 902 |
| T-cell receptor (TCR), 112, 181 |
| T-cells, 139, 149, 150, 151, 285, 921 |
| temozolomide, 228 |
| temsirolimus, 229, 283 |
| testicular lymphoma, 159, 422 |
| thiotepa, 9 |
| TRAIL, 167 |
| VEGFR, 167 |
| vinblastine, 68, 87 |
| Vinca alkaloids, 217 |
| Waldenström's macroglobulinemia (WM), 77, 108, 125, 194, 199, 200, 291, 344 |
| Waldeyer ring, 419 |
| zevalin, 457 |
Hematological Oncology
Explore this journal >
Supplement Article